Vir Biotechnology is an American clinical-stage immunology company that develops therapeutic products to treat and prevent serious infectious diseases. It was founded in 2016 and is headquartered in San Francisco, California.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
Vir Biotechnology news
08.05.2022
Vir Biotechnology's GAAP net profit for 3 months of 2022 was $518.621 million, compared to a loss of $168.911 million in the previous year. Revenue increased manifold to $1.233 billion from $0.002 billion a year earlier.
Source: 
investors.vir.bio
investors.vir.bio
25.02.2022
Vir Biotechnology's GAAP loss for 2021 was $528.584 million, up 77% from $298.665 million in the previous year. Revenue increased 14.4 times to $1.095 billion from $0.076 billion a year earlier.
Source: investors.vir.bio
investors.vir.bio
11.01.2022
The U.S. government has ordered another 600,000 doses of sotrovimab, developed by GlaxoSmithKline and Vir Biotechnology. The drug is designed to treat COVID-19 at an early stage. The companies will deliver additional doses during Q1 2022. In total, GSK and Vir have signed agreements to supply approximately 1.7 million doses of sotrovimab worldwide.
Source: investors.vir.bio
investors.vir.bio
General information
| Company name | Vir Biotechnology |
|---|---|
| Tags | #biotechnology |
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
| Business address | 499 Illinois Street Suite 500 San Francisco, CA 94158 United States |
| Mailing address | 499 Illinois Street Suite 500 San Francisco, CA 94158 United States |
| Website | investors.vir.bio |
English (US) 